Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Bristol-Myers Squibb is conducting a study titled ‘Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect)’ to evaluate the effectiveness of deucravacitinib in adults with moderate-to-severe plaque psoriasis in France. The study aims to provide real-world data on the treatment’s effectiveness, offering significant insights into its practical application.
Intervention/Treatment: The study focuses on the drug deucravacitinib, prescribed by clinicians to treat moderate-to-severe plaque psoriasis, assessing its real-world effectiveness.
Study Design: This is an observational study with a cohort model and a prospective time perspective. It aims to observe the outcomes of participants who have initiated deucravacitinib treatment over a two-year period.
Study Timeline: The study began on November 20, 2024, with an update submitted on April 10, 2025. These dates mark the recruitment phase and the latest update, indicating ongoing progress in data collection and analysis.
Market Implications: The study’s findings could influence Bristol-Myers Squibb’s stock performance by providing evidence of deucravacitinib’s effectiveness, potentially boosting investor confidence. This update may also impact the competitive landscape in the psoriasis treatment market, where real-world data is increasingly valued.
The study is currently recruiting, with further details available on the ClinicalTrials portal.